Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.

Inclusion Criteria: * Subjects must live in a geographical area where allergic problems caused by Juniperus oxycedrus and Cupressus arizonica are relevant. * Positive clinical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to asthma) to Juniperus oxycedrus and Cupressus arizonica. * A positive prick-test (mean papule diameter ≥ 3 mm) with an extract of the same allergen and/or presence of specific IgE against that allergen. * The mean papule area obtained with Histamine dichlorhydrate at 10 mg/mL should be ≥ 7 mm2. * Age: Between 18 and 64 years old. * Both sexes. * Subjects must be able to give informed consent. * Women of childbearing age (since menarche) must present a negative urine pregnancy test at the time of enrollment in the trial. Exclusion Criteria: * Subjects should not be excluded in terms of low or high sensitivity to Juniperus oxycedrus and Cupressus arizonica. * Subjects outside the age range. * Subjects who have previously received immunotherapy in the last 5 years for the treatment of asthma or rhinoconjunctivitis for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Juniperus oxycedrus and Cupressus arizonica extracts. * Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in which the suspension of the systemic antihistamine treatment is contraindicated. * Subjects who have previously presented a severe secondary reaction during the performance of diagnostic skin tests by prick test. * Subjects under treatment with ß-blockers. * Subjects clinically unstable (acute asthma, febrile, etc.). * Subjects with active urticaria lesions, severe active dermographism, severe atopic dermatitis, sunburn, eczema, psoriasis lesions in the area where the prick test is performed (risk of false positives). * Subjects with active viral infection by herpes simplex or herpes varicella zoster in the area where the prick test is performed. * Subjects with any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, HTA, cardiopathy, etc.). * States of the subject in which he/she cannot offer cooperation and severe psychiatric disorders. * Pregnant women or women at risk of pregnancy and lactating women.